Dasatinib
Who holds supplier records for Dasatinib? 20 organisations hold a current record for Dasatinib: an active US FDA Type II Drug Master File. A further 2 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (13), China (2) and Netherlands (1); not recorded for 4.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Dasatinib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/dasatinib
Reading the evidence
- 20 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
13 of the 16 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 13 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Dasatinib expires 22 Jan 2041. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (20)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Dasatinib. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Cipla LimitedIndia Company GMP cert on recordActive DMF 39133, 33589, 35219 · latest filing Nov 2023
- CDYMAX (INDIA) PHARMA PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 35990, 37942 · latest filing Jan 2023
- Granules India LimitedIndia Company GMP cert on recordActive DMF 35270, 38065 · latest filing Mar 2023
- Hetero Labs LimitedIndia Company GMP cert on recordActive DMF 32278, 41575 · latest filing Mar 2025
- Hubei Haosun Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 34875, 23763 · latest filing May 2020
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 32543, 32555 · latest filing Mar 2018
- TAPI NL BVNetherlandsActive DMF 32407, 31605 · latest filing Jan 2018
- Alembic Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 31282 · latest filing Mar 2017
- ALP PHARM BEIJING CO LTDActive DMF 29505 · latest filing Sept 2015
- APITORIA PHARMA PRIVATE LTDIndia Company GMP cert on recordActive DMF 34892 · latest filing May 2020
- BIOCARE PHARMACEUTICAL LTDChinaActive DMF 33644 · latest filing Mar 2019
- Biocon LimitedIndiaActive DMF 36185 · latest filing Sept 2021
- Deva Holding AsCompany GMP cert on recordActive DMF 39111 · latest filing Aug 2024
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 34676 · latest filing Mar 2020
- HIKMA PHARMACEUTICALS LLCActive DMF 30165 · latest filing Dec 2015
- Intas Pharmaceuticals Ltd.India Company GMP cert on recordActive DMF 35382 · latest filing Dec 2020
- Reliance Life Sciences Pvt. Ltd.India Company GMP cert on recordActive DMF 31169 · latest filing Mar 2017
- SHILPA PHARMA LIFESCIENCES LTDIndiaActive DMF 41834 · latest filing May 2025
- SICHUAN ELIXIR PHARMACEUTICAL CO LTDActive DMF 39646 · latest filing Mar 2024
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 33108 · latest filing Jan 2019
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (2)
Organisations whose Type II DMFs for Dasatinib are no longer active. These show a past filing, not current supply.
Show all 2 historical records
- China · Inactive DMF 28342 · filed Jun 2014
- Sichuan Xieli Pharmaceutical Co LtdChina · Inactive DMF 26494 · filed Sept 2012
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (66 listed products contain Dasatinib). The latest listed patent expires 22 Jan 2041. The latest listed exclusivity runs to 5 Dec 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Dasatinib is a tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with Philadelphia chromosome-positive (Ph+). It works by inhibiting the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality.
Chemical identity
- IUPAC name
- N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
- Canonical SMILES
- CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
- InChIKey
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N
- Synonyms
- Sprycel API, Dasatinib, Sprycel, Dasatinib anhydrous, BMS354825, Dasatinib (anhydrous), BMS 354825, dasatinibum, anh. dasatinib, anhydrous dasatinib, dasatinib (anh.), BMS Dasatinib
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Kinase Inhibitor
- Mechanism of action
- Cytochrome P450 3A4 Inhibitors; Protein Kinase Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Dasatinib?
20 organisations hold an active US FDA Type II Drug Master File or a CEP for Dasatinib: Cipla Limited (India), CDYMAX (INDIA) PHARMA PRIVATE LIMITED (India), Granules India Limited (India), Hetero Labs Limited (India), Hubei Haosun Pharmaceutical Co., Ltd. (China), MSN Laboratories Private Limited (India), TAPI NL BV (Netherlands) and Alembic Pharmaceuticals Limited (India), and 12 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Dasatinib Drug Master Files are active?
Cipla Limited (DMF 39133, 33589), CDYMAX (INDIA) PHARMA PRIVATE LIMITED (DMF 35990, 37942), Granules India Limited (DMF 35270, 38065), Hetero Labs Limited (DMF 32278, 41575), Hubei Haosun Pharmaceutical Co., Ltd. (DMF 34875, 23763), MSN Laboratories Private Limited (DMF 32543, 32555), TAPI NL BV (DMF 32407, 31605) and Alembic Pharmaceuticals Limited (DMF 31282) and 12 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Dasatinib records mean?
2 organisations have only inactive Type II DMFs for Dasatinib. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Dasatinib?
Yes. The latest patent listed for an approved US product containing Dasatinib expires 22 Jan 2041, across 66 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Dasatinib supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Dasatinib?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.